雌激素受体(ER)阳性乳腺癌患者的临床治疗选择 乳腺癌可根据雌激素受体(ER)、孕激素受体(PR)、人表皮生长因子受体2(HER2)的表达情况分为4种分子亚型:①管腔A型(ER+、PR+、HER2-),②管腔B型(ER+、PR+、HER2+),③三阴型(ER-、PR-、HER2-),④HER2过表达型(ER-、PR-、HER2+)。其中ER阳性乳腺癌约占所有...
therapy,however,the ER( + ) PR( + ) group had a signifi cant better survival than ER( 一) PR( + ) group if hormonal treat— ment was added into the treatment( DFS:P = 0.016,OS:P = 0.007) ,and both groups had better 5-year surv ival aner the ...
breast cancer\\{ER\\}\\{HER2\\}\\{PR\\}targeted treatmentThe application of targeted therapies has played important roles in the improvement of breast cancer survival rate during the past two decades. Estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor...
Ruta D. Rao, MD, and Virginia G. Kaklamani, MD, discuss with participants the case of a patient with breast cancer who has received multiple lines of therapy and what the next steps are for her treatment. CASE SUMMARY Initial presentation: A 56-year-old, postmenopausal woman presented ...
canbeaguideforthetreatmentofbreast cancer and is also an important indicator of prognosis. 【Key Words】 Breast cancer; ER; PR; HER一2; MGMT; GST一丌; P—gP; ToplI 乳腺癌是严重威胁妇女健康最常见 的恶性肿 瘤之 DOI :10 .3760/cma.j.issn.1674 —6090 .20 10 .0 1.003 ...
🔺ACS Journal Cancer官推转发该研究 🔺UWCCC专家针对该研究发表社论文章 UWCCC专家指出,2010年的ASCO/CAP指南建议,对细胞核ER或PR染色阳性≥1%的浸润性乳腺癌进行辅助内分泌治疗,但目前对1%～10%阳性肿瘤患者进行内分泌治疗的临床获益仍不确定...
19 Yu KD, Cai YW, Wu SY, Shui RH, Shao ZM. Estrogen receptor-low breast cancer: Biology chaos and treatment paradox. Cancer Commun (Lond). 2021;41(10):968-980. 专家简介 刘月平 主任医师/教授,医学博士,博士生导师 河北医科大学...
目的 探讨妇女外阴营养不良(增生型)在高强度聚焦超声(HIFU)治疗后上皮组织中孕激素受体(PR),雌激素受体(ER),核受体辅阻遏子(NCOR)及类固醇受体辅助活化因子-1(SRC-1)的表达及意义.方法 应用免疫组织方法,检测并比较正常妇女外阴上皮组织,外阴营养不良上皮组织及外阴营养不良HIFU治疗后上皮组织中PR,ER,NCOR和SRC...
For these reasons, the NCCN task force mandate22 that ER, PR and Her2 status be measured for every new case of breast cancer. While ER, PR, and Her2 status is routinely assessed by immunohistochemistry (IHC) staining for the receptors (Her2 can also be measured by FISH staining), we ...
A study on molecular subtype of breast carcinoma using ER, HER2, PR, and its relation with Ki67 Background: Using molecular biomarkers of breast cancer (BC) receives optimal treatment. Established biomarkers like estrogen receptor (ER), progesterone r... VHC Bagadi,S Karamchedu,R Fatima,.....